Rosuvastatin + Atorvastatin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia
Trial Timeline
Feb 1, 2006 → Jun 1, 2009
NCT ID
NCT00296400About Rosuvastatin + Atorvastatin
Rosuvastatin + Atorvastatin is a phase 2 stage product being developed by AstraZeneca for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00296400. Target conditions include Hyperlipidemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00683618 | Phase 3 | Completed |
| NCT00620542 | Phase 3 | Completed |
| NCT00427960 | Approved | Terminated |
| NCT00395486 | Approved | Completed |
| NCT00296400 | Phase 2 | Completed |
| NCT00296387 | Phase 3 | Completed |
| NCT00329173 | Phase 3 | Completed |
| NCT00239330 | Phase 3 | Completed |
| NCT00653965 | Phase 3 | Completed |
| NCT00653588 | Phase 3 | Completed |
| NCT00654225 | Phase 3 | Completed |
| NCT00654485 | Phase 3 | Completed |
| NCT00653744 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperlipidemia